Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled

PHASE3CompletedINTERVENTIONAL

Enrollment

215

Participants

Timeline

Start Date

May 4, 2016

Primary Completion Date

May 16, 2017

Study Completion Date

March 23, 2018

Conditions

Dyslipidemias

Interventions

DRUG

KI1106 4g, QD

KI1106 4 Capsules

DRUG

Atorvastatin Calcium 20mg, QD

Atorvastatin Calcium 20mg